Physician profile
Hannah Heusing
NPI 1487252367
$9,312.78
in general payments reported to CMS, 2019-2025
33 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,543 · 2022: $2,264 · 2023: $1,949 · 2024: $1,287 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,406 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,405.62 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,443.63 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,031.59 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,017.82 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $722.14 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $575.60 | 2021-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $564.28 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $545.32 | 2021-2022 | |
| Lundbeck LLC | $467.09 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $418.90 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $406.20 | 2021-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $389.34 | 2021-2025 | Ingrezza |
| Bausch Health US, LLC | $338.06 | 2021-2025 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $193.62 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Avanir Pharmaceuticals, INC. | $177.08 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $149.06 | 2021-2024 | Nuplazid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $93.42 | 2022-2025 | Qelbree, Qelbree |
| Biogen, INC. | $89.06 | 2023 | |
| Almatica Pharma LLC | $79.80 | 2021-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $75.80 | 2024-2025 | Cobenfy |
| Corium, LLC | $75.65 | 2022-2024 | Azstarys |
| Noven Therapeutics, LLC | $62.16 | 2025 | Xelstrym |
| Merck Sharp & Dohme LLC | $58.95 | 2021 | |
| Tris Pharma INC | $55.22 | 2024-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $50.69 | 2022-2023 | Adzenys Xr-Odt |
| Eisai INC. | $43.42 | 2021-2022 | |
| Tms Neurohealth Centers INC. | $38.66 | 2025 | Tms Neurohealth Centers INC. |
| Arbor Pharmaceuticals, INC. | $35.73 | 2021 | |
| Idorsia Pharmaceuticals US INC | $28.55 | 2023-2024 | Quviviq |
| Owp Pharmaceuticals, INC. | $23.74 | 2021 | |
| Collegium Pharmaceutical, INC. | $18.81 | 2025 | Jornay Pm |
| Gilead Sciences, INC. | $17.91 | 2021 | |
| Adlon Therapeutics L.P. | $12.76 | 2021 | |
| Aytu Biopharma, INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Heusing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.